S. Jelisavac-cosić

Followers

Following

Co-authors

Public Views

Kim M Cohen

Utrecht University

Armando Marques-Guedes

UNL - New University of Lisbon

Gabriel Gutierrez-Alonso

University of Salamanca

Peter D Clift

University College London

Pierre M . Vermeersch

KU Leuven

sabina porfido

Consiglio Nazionale delle Ricerche (CNR)

Beata Gruszka

Adam Mickiewicz University in Poznań

Stephen W Merkel

Vrije Universiteit Amsterdam

Nicola Scarselli

Royal Holloway, University of London

Michael Wagreich

University of Vienna

Interests

Uploads

Papers by S. Jelisavac-cosić

Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study

by S. Jelisavac-cosić and M. Sirotković-skerlev

Tumori

Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) are key mo... more Urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) are key molecules in pericellular proteolysis, a process that plays an important role in tumor invasion and metastasis. In the current study we investigated the prognostic significance of uPA and PAI-1 in primary invasive breast cancer. uPA and PAI-1 antigen levels were determined by enzyme-linked immunosorbent assay in cytosols of 177 invasive ductal carcinoma specimens. The prognostic significance of uPA and PAI-1 was assessed for overall survival. The median follow-up time was 90 months. In univariate analysis, both uPA (third versus first tertile range of values; P = 0.02; HR = 2.08) and PAI-1 (third versus first tertile; P = 0.0007; HR = 3.1) were significant prognostic markers for overall survival. In multivariate analysis only nodal status (N2 vs N0; P = 0.0001; HR = 3.94) and PAI-1 (third versus first tertile; P = 0.004; HR = 3.05) remained significant independent prognostic factors. Both ...

Prognostic significance of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer

European Journal of Cancer Supplements, 2004

Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients

by M. Sirotković-skerlev, S. Jelisavac-cosić, and D. Herceg

Medical oncology (Northwood, London, England), 2010

The aim of this study was to analyze the concentration of anti-p53 antibodies in the serum of bre... more The aim of this study was to analyze the concentration of anti-p53 antibodies in the serum of breast cancer patients and to correlate these results with various clinical, pathological and biochemical parameters. We also wanted to assess the prognostic significance of these antibodies in our patients. Sera from 61 patients with breast cancer and 20 individuals without malignancies were analyzed using enzyme-linked immunoadsorbent assay. High levels of anti-p53 antibodies were detected in twenty-one (35%) breast cancer patients and one control (5%). The difference was statistically significant. We observed an inverse relationship between the anti-p53 antibodies and the age of the patients. We found significant association of anti-p53 antibodies with tumor size, histological grade of the tumors and the number of axillary lymph nodes involved. The levels of anti-p53 antibodies were higher in patients with negative estrogen and progesterone receptors in comparison with patients with posi...